Patient‐Reported Symptom Burden and Objective Responses After Belumosudil in Heavily Pretreated Chronic GvHD
European Journal of Haematology · 11.11.2026
DOI: 10.1111/ejh.70355 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 11.11.2026. Verfasst von Sergio Rodriguez-Rodriguez und 15 weiteren Autor:innen. Beteiligte Einrichtung: University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Belumosudil has demonstrated clinical activity in chronic graft‐versus‐host disease (cGvHD), but its impact on patient‐reported symptom burden in routine practice remains incompletely characterized.
Objective
To evaluate longitudinal changes in cGvHD‐related symptom burden during belumosudil‐containing therapy, using the modified Lee symptom score (mLSS).
Methods
This retrospective, multicenter study included 87 heavily pretreated patients with cGvHD from four Canadian centers. We scored the mLSS at baseline and 3, 6, and 12 months after belumosudil initiation. Clinically meaningful improvement (CMI) was a ≥ 6‐point reduction in the overall mLSS. We analyzed longitudinal changes using a linear mixed‐effects model.
Results
Item‐level data were available for 48 patients (55%). Mean ± standard error mLSS decreased from 25.4 ± 1.8 at baseline to 16.5 ± 2.3 ( n = 25), 14.6 ± 3.0 ( n = 14), and 15.6 ± 4.5 ( n = 8) at 3, 6, and 12 months ( p < 0.001). CMI occurred in 52%, 64%, and 50% of evaluable patients, but in 15%, 10%, and 5% of all 87 treated patients. Best CMI was 65% ( n = 17/26) of evaluable patients and 20% of all treated patients, and best overall response rate was 41% ( n = 32/78).
Conclusions
Belumosudil‐containing therapy was associated with reduced symptom burden among patients with evaluable item‐level data. Declining data capture limits conclusions about durability and generalizability; prospective studies with systematic symptom burden capture are needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- University of Toronto, Toronto, Ontario, Canada.
- British Columbia Cancer Agency, Vancouver General Hospital, Vancouver, British Columbia, Canada.
- University of British Columbia, Vancouver, British Columbia, Canada.
- Hamilton Health Sciences, Juravinski Cancer Centre, Hamilton, Ontario, Canada.
- McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Sergio Rodriguez-Rodriguez, Mohamed Elemary, Eshrak Al-Shaibani, Tommy Alfaro-Moya, Arjun D Law, Igor Novitzky-Basso, Ivan Pasic, Auro Viswabandya, Fotios V Michelis, Rajat Kumar, Jonas Mattsson, Dennis D H Kim
Zitieren
APA
Rodriguez-Rodriguez, S., White, J., Lepic, K., Desai, N., Salter, B., Elemary, M., Al-Shaibani, E., Alfaro-Moya, T., Law, A. D., Novitzky-Basso, I., Pasic, I., Viswabandya, A., Michelis, F. V., Kumar, R., Mattsson, J., & Kim, D. D. H. (2026). Patient‐Reported Symptom Burden and Objective Responses After Belumosudil in Heavily Pretreated Chronic GvHD. European Journal of Haematology. https://doi.org/10.1111/ejh.70355
Vancouver
Rodriguez-Rodriguez S, White J, Lepic K, Desai N, Salter B, Elemary M, et al. Patient‐Reported Symptom Burden and Objective Responses After Belumosudil in Heavily Pretreated Chronic GvHD. European Journal of Haematology. 2026. doi:10.1111/ejh.70355
BibTeX
@article{RodriguezRodriguez2026,
author = {Rodriguez-Rodriguez, Sergio and White, Jennifer and Lepic, Kylie and Desai, Nihar and Salter, Brittany and Elemary, Mohamed and Al-Shaibani, Eshrak and Alfaro-Moya, Tommy and Law, Arjun D and Novitzky-Basso, Igor and Pasic, Ivan and Viswabandya, Auro and Michelis, Fotios V and Kumar, Rajat and Mattsson, Jonas and Kim, Dennis D H},
title = {Patient‐Reported Symptom Burden and Objective Responses After Belumosudil in Heavily Pretreated Chronic GvHD},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70355}
}
EUVIMED